Abstract
A peptide designed by German and U.S. researchers to disrupt interactions between two platelet-derived chemokines offers a new strategy to tackle atherosclerosis and has provided the foundation for a new biotech, Carolus Therapeutics.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
